1. As of December 2021, which of the following anti-SARS-CoV-2 monoclonal antibodies is expected to be effective against the Omicron Variant of Concern (VOC) for post-exposure prophylaxis?

2. For pharmacies without infusion centers, a subcutaneous administration option may provide additional options for patient access. Which of the following anti-SARS-CoV-2 monoclonal antibodies can be administered via subcutaneous administration?

3. Which of the following is NOT considered a disease state or health condition that, if present, can make a child or adult high risk to progression to severe COVID-19?

« Return to Activity